Inactive Instrument

Press Releases AEterna Zentaris Inc. Nasdaq

Equities

CA0079753038

End-of-day quote Nasdaq Other stock markets
- ^USD	-

06-13	Aeterna Zentaris Inc. Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	CI
06-03	Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	06-13	AQ
Aeterna Zentaris and Ceapro Complete Merger Transaction	06-03	AQ
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date	05-29	AQ
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro	05-17	AQ
Aeterna Zentaris : Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 - Form 6-K	05-16	PU
Aeterna Zentaris : Audited Consolidated Financial Statements of Ceapro Inc. as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 - Form 6-K	05-15	PU
Aeterna Zentaris Reports First Quarter 2024 Financial Results	05-14	AQ
Aeterna Zentaris : MATERIAL CHANGE REPORT - Form 6-K	05-09	PU
Aeterna Zentaris Announces Effective Date of Share Consolidation	05-01	AQ
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	03-27	AQ
Aeterna Zentaris : Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Form 6-K	03-27	PU
Aeterna Zentaris : Consolidated Financial Statements As of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 - Form 6-K	03-27	PU
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	03-12	AQ
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro	02-15	AQ
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders	12-14	BU
Canadian Investment Regulatory Organization Trade Resumption - AEZS	12-14	AQ
Canadian Investment Regulatory Organization Trading Halt - AEZS	12-14	AQ
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company	12-14	AQ
Aeterna Zentaris Reports Third Quarter 2023 Financial Results	11-09	AQ
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference	11/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AEterna Zentaris Inc. Nasdaq

Equities

CA0079753038

Press Releases

Filters